GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Agentix Corp (OTCPK:AGTX) » Definitions » Shiller PE Ratio

AGTX (Agentix) Shiller PE Ratio : (As of Dec. 14, 2024)


View and export this data going back to 2015. Start your Free Trial

What is Agentix Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Agentix Shiller PE Ratio Historical Data

The historical data trend for Agentix's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Agentix Shiller PE Ratio Chart

Agentix Annual Data
Trend Aug14 Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Mar23 Mar24
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Agentix Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Agentix's Shiller PE Ratio

For the Biotechnology subindustry, Agentix's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Agentix's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Agentix's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Agentix's Shiller PE Ratio falls into.



Agentix Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Agentix's E10 for the quarter that ended in Sep. 2024 is calculated as:

For example, Agentix's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.002/133.0289*133.0289
=-0.002

Current CPI (Sep. 2024) = 133.0289.

Agentix Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201411 -0.100 99.635 -0.134
201502 -0.100 99.032 -0.134
201505 -0.026 100.333 -0.034
201508 0.000 100.548 0.000
201511 -0.001 100.135 -0.001
201602 0.001 100.040 0.001
201605 -0.300 101.355 -0.394
201608 -0.200 101.617 -0.262
201611 -0.200 101.829 -0.261
201702 -0.300 102.779 -0.388
201705 -0.100 103.256 -0.129
201708 -0.100 103.587 -0.128
201711 -0.100 104.072 -0.128
201802 -0.100 105.052 -0.127
201805 -37.429 106.148 -46.908
201808 -0.015 106.383 -0.019
201811 -0.022 106.338 -0.028
201902 -0.040 106.649 -0.050
201905 -0.030 108.048 -0.037
201908 -0.008 108.245 -0.010
201911 -0.004 108.519 -0.005
202002 -0.009 109.139 -0.011
202005 -0.380 108.175 -0.467
202008 0.000 109.662 0.000
202011 -0.010 109.793 -0.012
202102 -0.020 110.968 -0.024
202105 -0.005 113.576 -0.006
202108 -0.010 115.421 -0.012
202111 -0.005 117.269 -0.006
202202 -0.050 119.703 -0.056
202206 -0.004 125.017 -0.004
202209 -0.010 125.227 -0.011
202212 -0.010 125.222 -0.011
202303 -0.020 127.348 -0.021
202306 -0.010 128.729 -0.010
202309 -0.004 129.860 -0.004
202312 0.000 129.419 0.000
202403 0.000 131.776 0.000
202406 -0.004 132.554 -0.004
202409 -0.002 133.029 -0.002

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Agentix  (OTCPK:AGTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Agentix Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Agentix's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Agentix Business Description

Traded in Other Exchanges
N/A
Address
32932 Pacific Coast Highway, No. 14-254, Dana Point, CA, USA, 92629
Agentix Corp is a biotechnology company. Through its subsidiary, it is engaged in the development and commercialization of novel therapeutics to treat metabolic diseases, peripheral neuropathy, progressive lung disease, and ischemic reperfusion injury. Its principal business objective is to develop both science-driven synthetic and natural cannabinoid therapeutics that address unmet medical needs and continue to drive innovations in the endocannabinoid space. Its pipeline of drug candidates includes AGTX-2004, a CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM), and AGTX-2003 a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease.
Executives
Thomas E Puzzo 10 percent owner 4216 NE 70TH STREET, SEATTLE WA 98115
Michael Winterhalter director, 10 percent owner, officer: President, CEO, CFO, Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Grays Peak Ventures Llc 10 percent owner 320 PARK AVE, NEW YORK NY 10022
Scott B Stevens director, officer: President and Director 9701 WILSHIRE BLVD., SUITE 1000, BEVERLY HILLS CA 90212
Robert K Whalen director, officer: Secretary and Treasurer 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Scott Thomas director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Robert Drust director 14 MONARCH BEACH PLAZA, SUITE 254, MONARCH BEACH CA 92629
Eric Krogius director, 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629
Bao Dong Han 10 percent owner 32932 PACIFIC COAST HIGHWAY, #14-254, DANA POINT CA 92629

Agentix Headlines

No Headlines